SCHEMBL2468652

SCHEMBL2468652

CC(=O)C1(N)CCc2ccccc21

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 3/20 0.44
MAPT P10636 2/20 0.44
CYP2C19 P33261 2/20 0.44
TDP1 Q9NUW8 2/20 0.44
ALDH1A1 P00352 1/20 0.44
POLB P06746 1/20 0.44
BLM P54132 1/20 0.44
GRM1 Q13255 1/20 0.44
MEN1 O00255 1/20 0.44
MAPK1 P28482 1/20 0.44
KMT2A Q03164 1/20 0.44
KDM1A O60341 2/20 0.44
MAOB P27338 1/20 0.43
HDAC9 Q9UKV0 1/20 0.43
HCAR2 Q8TDS4 1/20 0.41
CYP1A2 P05177 1/20 0.41
ALOX15 P16050 1/20 0.41
GRM2 Q14416 1/20 0.41
SIGMAR1 Q99720 1/20 0.39
TSHR P16473 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7448215 1.00 KDM4E (0.44) KDM4EMAPTCYP2C19TDP1ALDH1A1
SCHEMBL29677121 0.84 KDM4E (0.45) KDM4EMAPTCYP2C19TDP1ALDH1A1
SCHEMBL5310777 0.84 KDM4E (0.45) KDM4EMAPTCYP2C19TDP1ALDH1A1
SCHEMBL197941 0.84 KDM4E (0.61) KDM4EMAPTCYP2C19TDP1ALDH1A1
SCHEMBL197940 0.84 KDM4E (0.61) KDM4EMAPTCYP2C19TDP1ALDH1A1
SCHEMBL29380732 0.84 KDM4E (0.61) KDM4EMAPTCYP2C19TDP1ALDH1A1
SCHEMBL197942 0.84 KDM4E (0.61) KDM4EMAPTCYP2C19TDP1ALDH1A1
Hydrochloric Acid SCHEMBL17604963 0.82 KDM4E (0.59) KDM4EMAPTCYP2C19TDP1ALDH1A1
Hydrochloric Acid SCHEMBL4835592 0.82 KDM4E (0.59) KDM4EMAPTCYP2C19TDP1ALDH1A1
Hydrochloric Acid SCHEMBL4835584 0.82 KDM4E (0.59) KDM4EMAPTCYP2C19TDP1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
JP-4782252-B2 2011-09-28 JP claimed
US-6528685-B2 Such as (R)-N-(2-acetamido)-1-aminoindan for treatment of Parkinson's disease, dementia, epilepsy, convulsions, or seizures TEVA PHARMACEUTICAL INDUSTRIES, LTD. (IL) 2003-03-04 US claimed
EP-0738149-A4 1-AMINOINDAN DERIVATIVES AND COMPOSITIONS THEREOF TEVA PHARMA (IL) 1999-10-27 EP claimed
EP-0738149-A1 1-AMINOINDAN DERIVATIVES AND COMPOSITIONS THEREOF TEVA PHARMACEUTICAL INDUSTRIES, LTD. (IL) 1996-10-23 EP claimed
WO-1995018617-A1 1-AMINOINDAN DERIVATIVES AND COMPOSITIONS THEREOF TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) 1995-07-13 WO claimed
US-7964601-B2 Agonist or antgonist and binders and inversion of agonist PALATIN TECHNOLOGIES, INC. (US) 2011-06-21 US disclosed
US-7964601-B2 Agonist or antgonist and binders and inversion of agonist PALATIN TECHNOLOGIES, INC. (US) 2011-06-21 US disclosed
US-7897721-B2 Cyclic peptide compositions for treatment of sexual dysfunction PALATIN TECHNOLOGIES, INC. (US) 2011-03-01 US disclosed
US-7897721-B2 Cyclic peptide compositions for treatment of sexual dysfunction PALATIN TECHNOLOGIES, INC. (US) 2011-03-01 US disclosed
US-7807678-B2 Peptidomimetics of biologically active metallopeptides PALATIN TECHNOLOGIES, INC. (US) 2010-10-05 US disclosed
US-7807678-B2 Peptidomimetics of biologically active metallopeptides PALATIN TECHNOLOGIES, INC. (US) 2010-10-05 US disclosed
US-7795378-B2 Peptide compositions for treatment of sexual dysfunction PALATIN TECHNOLOGIES, INC. (US) 2010-09-14 US disclosed
US-20080234289-A1 Melanocortin Receptor-Specific Compounds PALATIN TECHNOLOGIES, INC. (US) 2008-09-25 US disclosed
US-7176279-B2 Cyclic peptide compositions and methods for treatment of sexual dysfunction PALATIN TECHNOLOGIES, INC. (US) 2007-02-13 US disclosed
US-7176279-B2 Cyclic peptide compositions and methods for treatment of sexual dysfunction PALATIN TECHNOLOGIES, INC. (US) 2007-02-13 US disclosed
EP-1242066-A4 USE OF 1-AMINOINDAN DERIVATIVES FOR TREATMENT OF MANIA IN BIPOLAR MOOD DISORDER TEVA PHARMA (IL) 2004-09-01 EP disclosed
EP-1242066-A1 USE OF 1-AMINOINDAN DERIVATIVES FOR TREATMENT OF MANIA IN BIPOLAR MOOD DISORDER TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) 2002-09-25 EP disclosed
WO-2001030339-A1 USE OF 1-AMINOINDAN DERIVATIVES FOR TREATMENT OF MANIA IN BIPOLAR MOOD DISORDER TEVA PHARMACEUTICAL INDUSTRIES, LTD. (IL) 2001-05-03 WO disclosed
WO-2000038673-A1 COMPOSITIONS CONTAINING AND METHODS OF USING N-ACYL-1H-AMINOINDENES TEVA PHARMACEUTICAL INDUSTRIES, LTD. (IL) 2000-07-06 WO disclosed
WO-1996021640-A1 OPTICALLY ACTIVE AMINOINDANE DERIVATIVES AND PREPARATION THEREOF TEVA PHARMACEUTICAL INDUSTRIES, LTD. (IL) 1996-07-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080234289-A1 Melanocortin Receptor-Specific Compounds MC1R, MC3R, MC5R KDM4E 1906/4885MAPT 1287/4885CYP2C19 1358/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.